A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
This is an open-label study to evaluate the safety, tolerability, and immunogenicity of
 INO-3112 DNA vaccines delivered by electroporation (EP) to female participants with HPV-16
 and/or 18-positive cervical carcinoma.
This is a Phase I/IIa, open-label study to evaluate the safety, tolerability, and
 immunogenicity of INO-3112 [VGX-3100 and INO-9012] delivered intramuscularly by
 electroporation in approximately 30 female participants with biopsy-proven, Stage IB-IVB
 inoperable invasive cervical carcinoma associated with HPV 16 and/or 18 who have completed
 treatment with standard chemoradiation therapy with curative intent (Cohort I) or in
 participants with persistent and/or recurrent cervical cancer associated with HPV 16 and/or
 18 following salvage therapy (Cohort II).
Inclusion Criteria:

 1. Written informed consent.

 2. Histological diagnosis of squamous cell carcinoma, adenocarcinoma or adenosquamous
 cell carcinoma of the cervix. Not accepted are small cell, clear cell and other rare
 variants of the classical adenocarcinoma.

 3. Histologically confirmed, Stage IB-IVB, invasive cervical carcinoma associated with
 HPV 16 and/or 18 and meet the following eligibility criteria for either Cohort 1 or
 Cohort 2.

 1. Cohort 1

 -  Newly diagnosed inoperable cervical cancer treated with chemoradiation
 therapy with curative intent and life expectancy of at least 12 months as
 assessed by the investigator

 -  No CNS/spinal metastases

 -  Able to initiate study treatment within 2 weeks of completion of last
 chemoradiation treatment

 2. Cohort 2

 -  Persistent and/or recurrent cervical cancer

 -  No CNS/spinal metastases

 -  Able to initiate study treatment at least 2 weeks but no more than 4 weeks
 after completion of salvage therapy

 -  Life expectancy of at least 12 months as assessed by the investigator

 4. Electrocardiogram (ECG) with no clinically significant findings.

 5. Chemistry, liver function tests, renal function, total CPK and hematology lab results
 must be ≤ Grade 1 at the time of screening.

 6. Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1.

 7. Adequate venous access for repeated blood sampling according to the study schedule.

 8. Women of child-bearing potential must have a negative serum pregnancy test and agree
 to remain sexually abstinent, have a partner who is sterile (i.e., vasectomy), or use
 two medically effective methods of contraception (e.g., oral contraception, barrier
 methods, spermicide, intrauterine device [IUD]).

 9. Able and willing to comply with all study procedures.

 Exclusion Criteria:

 1. Pregnancy or breastfeeding.

 2. History of previous therapeutic HPV vaccination.

 3. Prior exposure to an investigational agent or device within 30 days of signing the
 ICF. Of note, the participant may participate in observational studies.

 4. Positive serological test for HIV, Hep B or Hep C or history of HIV infection,
 Hepatitis B or Hepatitis C (women with cured HCV will be allowed; participant must
 have had a serologic test performed within 12 months of informed consent).

 5. Prior major surgery from which the participant has not yet recovered to baseline.

 6. High medical risks because of non-malignant systemic disease or with active
 uncontrolled infection.

 7. Current malignancies at other sites, with the exception of adequately treated basal or
 squamous cell carcinoma of the skin.

 8. Congestive heart failure or prior history of New York Heart Association (NYHA) class
 III/ IV cardiac disease.

 9. Use of topical corticosteroids at or near the intended administration site.

 10. Any cardiac pre-excitation syndromes (such as Wolff-Parkinson-White).

 11. History of seizures (unless seizure free for 5 years).

 12. Tattoos or scars within 2 cm of the intended site of injection or if there is
 implanted metal within the same limb. Any device implanted in the chest (e.g., cardiac
 pacemaker or defibrillator) excludes the use of the deltoid muscle on the same side of
 the body.

 13. Active drug or alcohol use or dependence.

 14. Imprisonment or compulsory detainment for treatment of either a psychiatric or
 physical (i.e. infectious disease) illness.

 15. History of immunosuppressive or autoimmune disease.

 16. Any other illnesses or conditions that in the opinion of the investigator may affect
 the safety of the participant or limit the evaluation of a participant or any study
 endpoint.